Brain volume is related to neurological impairment and to copper overload in Wilson’s disease

Lukasz Smolinski¹ · Tomasz Litwin¹ · Barbara Redzia-Ogrodk¹ · Karolina Dzieycz¹ · Iwona Kurkowska-Jastrzebska¹ · Anna Czlonkowska¹

Received: 9 November 2018 / Accepted: 16 May 2019 / Published online: 30 May 2019

Abstract

Introduction To determine whether brain volume was associated with functional and neurological impairments and with copper overload markers in patients with Wilson’s disease.

Methods In 48 treatment-naïve patients, we assessed functional and neurological impairments with the Unified Wilson’s Disease Rating Scale, measured normalized brain volumes based on magnetic resonance images, and assessed concentration of non-ceruloplasmin-bound copper. We correlated brain volume measures with functional and neurological impairment scores and copper overload indices.

Results Functional and neurological impairments correlated with all brain volume measures, including the total brain volume and the volumes of white matter and gray matter (both peripheral gray matter and deep brain nuclei). Higher non-ceruloplasmin-bound copper concentrations were associated with greater functional and neurological impairments and lower brain volumes.

Conclusions Our findings provided the first in vivo evidence that the severity of brain atrophy is a correlate of functional and neurological impairments in patients with Wilson’s disease and that brain volume could serve as a marker of neurodegeneration induced by copper.

Keywords Wilson’s disease · Unified Wilson’s disease rating scale · Volumetric MRI

Introduction

Wilson’s disease (WD) is an autosomal recessive disorder caused by mutations in the gene that encodes ATPase 7B (ATP7B), the membrane-bound copper transporter [1]. This enzyme, expressed in the liver, plays a central role in copper trafficking. It delivers copper to apoceruloplasmin and excretes excess dietary copper into the bile [2]. In WD, dysfunction of ATP7B leads to hypoceruloplasminemia and insufficient copper removal from liver cells, which results in liver injury; consequently, copper is released into the blood in the form of non-ceruloplasmin-bound copper (NCC), which accumulates and causes damage to other tissues, particularly the brain [2]. Thus, patients with WD present with hepatic and/or neurological symptoms and may have corneal copper deposits (Kayser-Fleisher rings) [1, 2].

On brain magnetic resonance images (MRIs) of patients with WD, bilateral T2-hyperintensities are typically observed in the deep brain structures [3–5], and widespread brain atrophy is also commonly observed [5–7]. Compared to healthy controls, brains of patients with WD display reduced volumes in the caudate nuclei, globi pallidi, thalami, cerebellum, and cerebral cortex [8]. Previous research has shown that brain volume correlates with clinical impairment in different neurological diseases. In multiple sclerosis, whole brain volume, the volumes of gray and white matter, and thalamic volume correlate with disease severity [9]. In Alzheimer’s disease, hippocampal volume is related to cognitive function [10], and motor impairment is related to whole brain volume and the volume of gray matter in patients with progressive supranuclear palsy [11]. In this study, we aimed
to determine whether a similar relationship is observed in WD. To that end, we correlated brain volume measures with functional and neurological impairments, assessed using the Unified Wilson’s Disease Rating Scale (UWDRS), [12, 13] in a relatively large group of treatment-naïve patients with WD. We also investigated whether brain atrophy was associated with indices of copper overload.

**Methods**

**Participants**

In this cross-sectional study, we analyzed prospectively collected data of 48 patients with WD. We included consecutive treatment-naïve adult patients diagnosed with WD in our department, after the introduction of a consistent brain imaging protocol, between December 2011 and December 2016. WD was diagnosed and classified into one of three clinical phenotypes (i.e., presymptomatic, predominantly hepatic, and predominantly neurological) according to international recommendations [14]. In addition, patients with the neurological phenotype were further classified based on the predominant neurological syndrome type based on classifications described by Marsden [15] and Oder et al. [16], i.e., tremor (including patients with predominant tremor and ataxia), parkinsonism (including rigidity, rest tremor and hypokinesia), and dystonia (including choreoathetosis) [17]. Disease duration was defined as the time from first hepatic or neurological symptoms, which did not prompt a diagnostic work-up, to the time of diagnosis. The presence of corneal copper deposits in either eye (the Kayser-Fleischer ring) was determined by an ophthalmologist in a slit-lamp examination. The study was approved by the Bioethics Committee of the Institute of Psychiatry and Neurology, Warsaw. We included only data of patients that provided signed consent to use their clinical and laboratory data for research purposes.

**Rating of neurological and functional impairment**

Before treatment initiation, the UWDRS [12, 13] was used to rate functional impairment (UWDRS_FI, items 2–11; part 2 of the UWDRS), with respect to activities of daily living, and neurological impairment (UWDRS_NI, items 12–35; part 3 of the UWDRS). On both subscales, higher scores indicated greater impairments.

**Copper metabolism**

Serum concentrations of copper were measured by atomic absorption spectrophotometry, and serum ceruloplasmin concentrations were measured in an enzyme-based colorimetric assay [18]. The concentration of NCC was calculated according to a standard formula: NCC (µg/dl) = total serum copper (µg/dl) – 3.15 × serum ceruloplasmin (mg/dl) [1].

**Image acquisition and image analysis**

All images were acquired according to a consistent protocol with a 1.5-T magnetic resonance imaging scanner (Achieva, Phillips, 8-channel head coil; see Suppl. Table 1 for sequence parameters). Based on the T1-weighted axial images, we estimated normalized brain volume (NBV), white matter (WM), gray matter (GM), peripheral gray matter (PGM), and ventricular cerebrospinal fluid (vCSF) with the cross-sectional version of Structural Image Evaluation using Normalization of Atrophy (SIENAX) provided in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library [19]. Because some scans did not provide complete brain coverage, all SIENAX analyses were performed within a predefined range of standard space-Z coordinates (MNI space-Z coordinates between −60 mm and 60 mm; ~95% of brain volume coverage, Suppl. Fig. 1). As MRI scans were not acquired prospectively with a consistent positioning protocol, in each case, we manually specified the center of gravity and used eye removal in the brain extraction step of SIENAX (options -c and -S). For all analyses, we used volumes that were normalized for head size by multiplying non-normalized volumes by subject-specific skull-scaling factors, derived with SIENAX [19, 20]. We calculated the brain parenchymal fraction (BPF) according to the following formula: BPF = NBV/(NBV + vCSF volume). The volumes of the thalami, caudate nuclei, globi pallidi, and putamina were estimated with FMRIB’s Integrated Registration and Segmentation Tool (FIRST) (Suppl. Fig. 1) according to a protocol optimized for two-dimensional images [21]. The total volume of these structures was used to estimate the volume of deep gray matter (DGM). In all cases, the results of brain image extraction and segmentation were visually inspected for quality control.

**Statistical analysis**

Correlations between clinical measures, brain volumes, and laboratory measures were calculated with the Spearman rank correlation coefficient, rho; correlations were considered weak for rho ≤ 0.3, moderate for 0.3 < rho < 0.6, and strong for rho ≥ 0.6. To control for the effects of sex and age at diagnosis, we calculated partial Spearman correlation coefficients (rho_p) and performed an analysis of covariance (ANCOVA). ANCOVAs were used to compare brain measures between sexes. The significance level was set at p < 0.05 (two-tailed). All analyses were performed with R (v3.3.2) software.
Results

Characteristics of participants

Demographic, clinical, and laboratory characteristics of participants are presented in Table 1. The mean age was 33.4 years and 54% were males. Approximately half (48%) of the patients studied had a predominantly neurological WD phenotype, with 6 patients exhibiting no symptoms. As expected, median serum ceruloplasmin concentrations were below the normal range, whereas mean NCC concentrations were above the upper limit of normal (15 μg/dL).

Relationship between brain volume parameters and age or sex

Age was significantly associated with decreased brain volume for NBV, BPF, GM, WM, PGM, and DGM but not for vCSF volume (Suppl. Table 2). Compared to women, men had a significantly lower age-adjusted volume of DGM ($p = 0.002$) and a significantly higher volume of vCSF ($p = 0.044$), and showed a trend of lower BPF values, although the difference was not statistically significant ($p = 0.05$). The remaining brain parameters did not differ significantly between sexes. None of the brain volumes correlated significantly with disease duration, also when corrected for sex and age (data not shown).

Relationship between brain volume and functional and neurological impairments

Neurological impairment, rated on the UWDRS_NI scale, correlated strongly with NBV, the BPF, and the vCSF volume (Fig. 1a–c). There were moderate correlations between the UWDRS_NI scores and the volumes of WM, GM, PGM, and DGM (Fig. 1g–j). Similarly, functional impairment, rated on the UWDRS_FI scale, correlated with all the analyzed brain volumes (Table 2).

Table 1  Demographic, clinical, and laboratory characteristics of 48 patients with Wilson's disease

| Characteristic                                                                 | Mean ± SD, unless otherwise stated |
|-------------------------------------------------------------------------------|-----------------------------------|
| Mean age, years                                                               | 33.37 ± 12.28                     |
| Gender, male, N (%)                                                           | 26 (54)                           |
| Mean disease duration, years                                                  |                                   |
| Predominantly hepatic                                                         | 3.00 ± 2.47                       |
| Predominantly neurological                                                    | 5.33 ± 6.98                       |
| Disease phenotype, N (%)                                                      |                                   |
| Presymptomatic                                                               | 6 (12)                            |
| Predominantly hepatic                                                         | 19 (40)                           |
| Predominantly neurological                                                    | 23 (48)                           |
| Predominant neurological form, N (% of patients with neurological symptoms)  |                                   |
| Ataxia/tremor                                                                 | 10 (43)                           |
| Parkinsonism                                                                  | 8 (35)                            |
| Dystonia                                                                      | 4 (17)                            |
| Unclassified                                                                  | 1 (4)                             |
| Kayser-Fleischer rings,                                                        |                                   |
| Presymptomatic, N (%)                                                         | 1 (17)                            |
| Predominantly hepatic, N (%)                                                  | 7 (58)                            |
| Predominantly neurological, N (%)                                             | 23 (100)                          |
| Median UWDRS_NI score (range)                                                 | 5 (0–46)                          |
| Median UWDRS_FI score (range)                                                 | 0 (0–14)                          |
| Serum ceruloplasmin concentration, mg/dl; normal range: 25–45 mg/dl          | 13.6 ± 7.10$^a$                   |
| Total serum copper concentration, μg/dl; normal range: 70–140 μg/dl           | 59.57 ± 21.27                     |
| Non-ceruloplasmin-bound copper concentration, μg/dl                           | 16.05 ± 10.6$^b$                  |
| Corneal copper deposits, N (%)                                                | 36 (75)                           |

$^a$ We excluded data that were not acquired in our laboratory (one patient)

$^b$ We excluded data that were not acquired in our laboratory (one patient) and data of one patient with non-ceruloplasmin-bound copper concentration that was over 5 standard deviations above the mean (73.4 μg/dl)
Importantly, nearly all correlations between the brain volume measures and scores of neurological and functional impairments remained significant after controlling for age and sex ($\rho_{p}$ values, Table 3).
Relationship between copper metabolism, functional and neurological impairments, and brain volume

The NCC concentration was negatively correlated with both UWDRS_FI and UWDRS_NI scores (rho = -0.295, \( p = 0.046 \) and rho = -0.315, \( p = 0.033 \), respectively; age- and sex-adjusted rho = -0.318, \( p = 0.035 \) and rho = -0.382, \( p = 0.011 \), respectively). We found that the NCC concentration was significantly associated with the BPF (rho = -0.389, \( p = 0.008 \)) and the vCSF volume (rho = 0.420, \( p = 0.004 \); Fig. 1k and l). These correlations remained significant after controlling for age and sex (rho = -0.456, \( p = 0.002 \) for BPF; rho = 0.475, \( p = 0.001 \) for vCSF). In addition, after controlling for age and sex, trends indicated that NCC could be associated with PGM (rho = -0.295, \( p = 0.052 \)). The remaining brain volume measures were not significantly associated with NCC (data not shown). We did not find any significant relationship between the analyzed brain volume measures and serum concentrations of ceruloplasmin or total copper.

**Discussion**

This study for the first time investigated the relationship between brain volumes and disease severity and copper metabolism in WD. Our findings showed that the volumes of all the major brain structures correlated with functional and neurological impairments in treatment-naïve patients with WD. In addition, brain volume could be viewed as a marker of copper-induced neurodegeneration due to WD, because lower brain volume was observed in patients with higher NCC concentrations.

Previous studies have attempted to investigate the relationship between neuroimaging results and the degree of neurological impairment in WD. However, they did not use validated tools, and/or they included heterogeneous patient samples (e.g., patients treated with different agents) [7, 22, 23]. In particular, previous studies did not investigate whether the severity of brain atrophy was related to the functional and neurological states of patients with WD or to NCC. Moreover, except for the study by Stezin [8], previous studies assessed brain atrophy in WD subjectively (presence vs. absence) [6, 7, 23]. We addressed these issues by evaluating neurological and functional states with a disease-specific clinical scale (UWDRS) and by quantitatively measuring brain volumes (with SIENAX and FIRST tools) in treatment-naïve patients with WD.

In our study, the total brain volume and the WM and GM volumes (both PGM and DGM; Fig. 1d-j) showed comparable relevance to the functional and neurological states of patients. This finding was consistent with the diffuse nature of brain atrophy described in patients with WD [5, 6, 9]. A likely explanation might be that copper accumulates equally in all brain regions in patients with WD [24], which leads to damage in both WM and GM; indeed, neuronal loss, axonal disruption, and multifocal demyelination are potential causes of brain atrophy [25, 26]. Moreover, in an earlier study, we found that greater neurological impairment severity in WD was associated with decreased retinal nerve fiber layer thickness [27]. That finding led us to suspect that, in WD, brain volume might be correlated with retinal nerve fiber layer thickness, as it is, for instance, in multiple sclerosis [28]. The strong correlation we found between brain volume and neurological and functional states suggested that brain volume measures could potentially become valuable endpoints in clinical trials in WD. This approach could decrease the sample size needed to demonstrate a treatment effect. However, measuring the effect would require longitudinal analyses to show that changes in brain volume over time were correlated with changes in the clinical state.

Similar to earlier studies, we found that age was associated with decreasing volumes of all the studied brain compartments [29, 30]. Also, in our study, male sex was a risk

| Table 2 | Spearman rank correlation coefficients for associations between functional impairment scores and brain volume measures in patients with Wilson’s disease |
|---------|---------------------------------------------------------------|
| NBV    | BPF   | vCSF  | GM   | WM   | PGM  | DGM  |
| UWDRS_FI | -0.388 | -0.622 | 0.634 | -0.236 | -0.399 | -0.325 | -0.458 |
| p      | 0.006  | <0.0001 | <0.0001 | 0.110 | 0.005 | 0.024 | 0.001 |

**UWDRS_FI** Unified Wilson’s Disease Rating Scale—functional impairment, **NBV** normalized brain volume, **BPF** brain parenchymal fraction, **vCSF** ventricular cerebrospinal fluid, **GM** gray matter, **WM** white matter, **PGM** peripheral gray matter, **DGM** deep gray matter.
factor for decreased DGM and increased vCSF volumes. This added to our previous findings in WD that males, more frequently than females, showed neuroimaging abnormalities [6] and had a higher risk of developing neurological symptoms [31]. However, in this study, we could not find a feasible explanation for the inter-sex differences regarding the two brain volumes. First, these differences were not found in healthy individuals in a previous study that employed a similar method [32]. Second, deep brain nuclei were shown to be affected in WD to the same extent in both sexes [6]. Thus, further research is needed to evaluate deep brain nuclei in WD.

Copper toxicity is the key pathogenic mechanism in WD, and we showed herein that it was also related to brain atrophy and neurological and functional impairments at diagnosis. Indicators of total brain volume (i.e., BPF) and vCSF volume were significantly negatively and positively correlated, respectively, with the NCC concentration, which is typically elevated in untreated patients with WD. Similarly, PGM volume tended to be lower in patients with higher NCC concentrations.

Our study had limitations. First, it was retrospective, which in principle, can lead to selection bias, data inhomogeneity, and missing data. However, we collected neuroimaging and clinical data in our cohort in a prospective manner according to a standardized protocol. Therefore, we could retrieve data relevant to this study for all consecutive patients examined during the studied period. To preserve the homogeneity of data, we did not include copper metabolism data from patients treated with anti-copper agents or any data that were not acquired in our center. Second, in statistical terms, the study sample was small; however, WD is rare, and our sample of treatment-naive patients was relatively large in comparison to earlier studies on WD. Third, the measurement of NCC concentration—one of the serum copper overload indices—was not standardized, which could lead to different findings between different laboratories [33]. However, all measurements of ceruloplasmin and copper in our study were consistently conducted in the same laboratory. Lastly, we did not assess cognitive function, which could be related to brain volume in WD.

In conclusion, our findings provided the first in vivo evidence that the severity of brain atrophy is an important correlate of neurological and functional impairments in patients with WD. Our findings also suggested that brain volume can serve as a marker of copper toxicity. In the future, longitudinal studies should be conducted to determine whether brain volume changes over time correlate with the changes in the clinical state.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Table 3 Partial Spearman rank correlation coefficients (\(\rho\)) for associations between functional and neurological impairment scores and brain volume measures (corrected for age and sex)

| UWDRS_FI | NBV | BPF | vCSF | GM | WM | PGM | DGM |
|----------|-----|-----|------|----|----|-----|-----|
|          | −0.383 | −0.609 | 0.623 | −0.236 | −0.390 | −0.297 | −0.442 |
|          | \(p = 0.009\) | \(p < 0.0001\) | \(p < 0.0001\) | \(p = 0.118\) | \(p = 0.008\) | \(p = 0.045\) | \(p = 0.002\) |
| UWDRS_NI | −0.559 | −0.674 | 0.677 | −0.359 | −0.540 | −0.392 | −0.468 |
|          | \(p < 0.0001\) | \(p < 0.0001\) | \(p < 0.0001\) | \(p = 0.015\) | \(p < 0.001\) | \(p = 0.007\) | \(p = 0.001\) |

UWDRS_FI Unified Wilson’s Disease Rating Scale—functional impairment, UWDRS_NI Unified Wilson’s Disease Rating Scale—neurological impairment, NBV normalized brain volume, BPF brain parenchymal fraction, vCSF ventricular cerebrospinal fluid, GM gray matter, WM white matter, PGM peripheral gray matter, DGM deep gray matter

References

1. European Association for Study of Liver (2012) EASL clinical practice guidelines: Wilson’s disease. J Hepatol 56:671–685. https://doi.org/10.1016/j.jhep.2011.11.007
2. Bandmann O, Weiss KH, Kaler SG (2015) Wilson’s disease and other neurological copper disorders. Lancet Neurol 14:103–113. https://doi.org/10.1016/S1474-4422(14)70190-5
3. da Costa M do DL, Spitz M, Bacheschi LA, et al (2009) Wilson’s disease: two treatment modalities. Correlations to pretreatment and posttreatment brain MRI. Neuroradiology 51:627–633. doi: https://doi.org/10.1007/s00234-009-0536-5
4. Saatci I, Topcu M, Baltaoglu FF, Kose G, Yalaz K, Renda Y, Besim A (1997) Cranial MR findings in Wilson’s disease. Acta Radiol 38:250–258
5. Sinha S, Taly AB, Prashanth LK, Ravishankar S, Arunodaya GR, Vasudev MK (2007) Sequential MRI changes in Wilson’s disease
with de-coppering therapy: a study of 50 patients. Br J Radiol 80:744–749. https://doi.org/10.1259/bjr/48911350
6. Litwin T, Gromadzka G, Czonkowska A, Golbiakowski M, Poniątowska R (2013) The effect of gender on brain MRI patholo-
gy in Wilson’s disease. Metab Brain Dis 28:69–75. https://doi.
.org/10.1007/s11011-013-9378-2
7. Starosta-Rubinstein S, Young AB, Kluin K, Hill G, Aisen AM, Gabrielsen T, Brewer GJ (1987) Clinical assessment of 31 patients
with Wilson’s disease. Correlations with structural changes on mag-
netic resonance imaging. Arch Neurol 44:365–370
8. Stezin A, George L, Jhunjhunwala K, Lenka A, Saini J, Netravathi M, Yadav R, Pal PK (2016) Exploring cortical atrophy and its
clinical and biochemical correlates in Wilson’s disease using voxel
based morphometry. Parkinsonism Relat Disord 30:52–57. https://
doi.org/10.1016/j.parkreldis.2016.06.017
9. Nakamura Y, Gaetano L, Matsushita T, Anna A, Sprenger T, Radue EW, Wuerfel J, Bauer L, Amann M, Shinoda K, Isobe N, Yamasaki R, Saida T, Kappos L, Kira JI (2018) A comparison of brain mag-
netic resonance imaging lesions in multiple sclerosis by race with
reference to disability progression. J Neuroinflammation 15:255.
https://doi.org/10.1186/s12974-018-1295-1
10. Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, Guevara C, Bulatova K, Barker GJ, Gonzalez G, Crossley NA,
ł
11. Guevara C, Bulatova K, Barker GJ, Gonzalez G, Crossley NA, Kempton MJ (2016) Whole-brain atrophy differences between pro-
gressive supranuclear palsy and idiopathic Parkinson’s disease.
Front Aging Neurosci 8:218. https://doi.org/10.3389/fnagi.2016.
00218
12. Czonkowska A, Tarnacka B, Möller JC et al (2007) Unified
Wilson’s disease rating scale - a proposal for the neurological scoring
of Wilson’s disease patients. Neurol Neurochir Pol 41:1–12
13. Leinweber B, Möller JC, Scherag A, Reuner U, Günther P, Lang CJG, Schmidt HHI, Schrader C, Bandmann O, Czonkowska A, Oertel WH, Heffer H (2008) Evaluation of the unified Wilson’s
disease rating scale (UWDRS) in German patients with treated
Wilson’s disease. Mov Disord 23:54–62. https://doi.org/10.1002/
mds.21761
14. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F (2003) Diagnosis and phe-
notypic classification of Wilson disease. Liver Int 23:139–142
15. Marsden CD (1987) Wilson’s disease. Q J Med 65:959–966
16. Oder W, Prayer L, Grimm G, Spatt J, Ferenci P, Kollegger H, Schneider B, Gandel A, Deecke L (1993) Wilson’s disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 43:120–124
17. Czonkowska A, Litwin T, Dzieżyc K, Karlinski M, Bring J, Bjaatmar C (2018) Characteristics of a newly diagnosed polish
cohort of patients with neurological manifestations of Wilson dis-
ease evaluated with the unified Wilson’s disease rating scale. BMC Neurosci 18:34. https://doi.org/10.1186/s12888-018-1039-y
18. Ravin HA (1961) An improved colorimetric enzymatic assay of
ceruloplasmin. J Lab Clin Med 58:161–168
19. Zhang Y, Brady M, Smith S (2001) Segmentation of brain MR
images through a hidden Markov random field model and the
expectation-maximization algorithm. IEEE Trans Med Imaging
20:45–57. https://doi.org/10.1109/42.906424
20. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, Bannister PR, de Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, de
Stefano N, Brady JM, Matthews PM (2004) Advances in functional
and structural MR image analysis and implementation as FSL.
Neuroimage 23:S208–S219. https://doi.org/10.1016/j.neuroimage.
2004.07.051
21. Amann M, Andelová M, Pfister A, Mueller-Lenne N, Traud S, Reinhardt J, Magon S, Bendfeldt K, Kappos L, Radue EW, Stippich C, Sprenger T (2015) Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB’s integrated registration and segmentation tool (FIRST). Neuroimage 7:43–52. https://doi.org/10.1016/j.neuroimage.2014.11.010
22. Sinha S, Taly AB, Ravishankar S, Prashanth LK, Venugopal KS, Arunodaya GR, Vasudev MK, Swamy HS (2006) Wilson’s disease:
cranial MRI observations and clinical correlation. Neuroradiology
48:613–621. https://doi.org/10.1007/s00234-006-0101-4
23. King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID, Halligan S, Hall-Craggs MA (1996) Cranial MR
imaging in Wilson’s disease. Am J Roentgenol 167:1579–1584.
https://doi.org/10.2214/ajr.167.6.8956601
24. Litwin T, Gromadzka G, Szpak GM, Jablonka-Salak K, Bulska E, Czonkowska A (2013) Brain metal accumulation in Wilson’s
disease. J Neurol Sci 329:55–58. https://doi.org/10.1016/j.jns.2013.
03.021
25. Meenakshi-Sundaram S, Mahadevan A, Taly AB, Arunodaya GR, Swamy HS, Shankar SK (2008) Wilson’s disease: a cliniconeuropathological autopsy study. J Clin Neurosci 15:409–417.
https://doi.org/10.1016/j.jocn.2006.07.017
26. Mikol J, Vital C, Wassef M, Chappuis P, Poupon J, Lecharpentier M, Womimant F (2005) Extensive cortico-subcortical lesions in
Wilson's disease: clinicopathological study of two cases. Acta
Neuropathol 110:451–458. https://doi.org/10.1002/ana.20511
27. Langwińska-Wośko E, Litwin T, Dzieżyc K, Karlinski M, Czonkowska A (2017) Optical coherence tomography as a marker
of neurodegeneration in patients with Wilson’s disease. Acta
Neurrol Belg 117:867–871. https://doi.org/10.1007/s13760-017-
0788-5
28. Saidha S, Al-Louzi O, Ratchford JN et al (2015) Optical coherence
tomography reflects brain atrophy in multiple sclerosis: a four-year
study. Ann Neurol 78:801–813. https://doi.org/10.1002/ana.24487
29. Lee H, Prohovnik I (2008) Cross-validation of brain segmentation
by SPM5 and SIENAX. Psychiatry Res 164:172–177. https://doi.
.org/10.1016/j.psychres.2007.12.008
30. Goodro M, Sameti M, Patenaude B, Fein G (2012) Age effect on
subcortical structures in healthy adults. Psychiatry Res 203:38–45.
https://doi.org/10.1016/j.pscychresns.2011.09.014
31. Litwin T, Gromadzka G, Czonkowska A (2012) Gender differ-
ences in Wilson's disease. J Neurol Sci 312:31–35. https://doi.
.org/10.1016/j.jns.2011.08.028
32. Király A, Szabó N, Tóth E, Csete G, Faragó P, Kocsis K, Must A, Vécsei L, Kincses ZT (2016) Male brain ages faster: the age and
gender dependence of subcortical volumes. Brain Imaging Behav
10:901–910. https://doi.org/10.1007/s11862-015-0498-3
33. Twomey PJ, Viljoen A, Reynolds TM, Wierzbicki AS (2008) Non-
ceruloplasmin-bound copper in routine clinical practice in different
laboratories. J Trace Elem Med Biol 22:50–53. https://doi.org/10.
1016/j.jtemb.2007.11.001
Publisher's note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.